To improve outcomes and efficacy of treatment of primary and/or metastatic parotid SCC, systematic studies involving larger series of HER2+ salivary gland cancers or stratification of patients to HER2-targeted therapies by alternative strategies are needed to determine the contribution of HER2 targeting on tumor response outcomes in parotid SCC and other salivary gland cancers (17). The gene discussed is ERBB2; the disease is neoplasm.